[
  {
    "ts": "2025-09-18T21:50:05+00:00",
    "headline": "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior day's close.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-gild-outpaces-stock-215005948.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2a47013a-6eee-30c6-86aa-c59a52094fb0",
      "content": {
        "id": "2a47013a-6eee-30c6-86aa-c59a52094fb0",
        "contentType": "STORY",
        "title": "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know",
        "description": "",
        "summary": "Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior day's close.",
        "pubDate": "2025-09-18T21:50:05Z",
        "displayTime": "2025-09-18T21:50:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uV6mPOIlsfK8Kl7nmlunJw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sc4z8_.3guA7NR27rd8O3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-outpaces-stock-215005948.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-outpaces-stock-215005948.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-18T13:00:04+00:00",
    "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know",
    "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/investors-heavily-search-gilead-sciences-130004097.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "13ec6566-2407-3235-b64d-bc59254518ad",
      "content": {
        "id": "13ec6566-2407-3235-b64d-bc59254518ad",
        "contentType": "STORY",
        "title": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know",
        "description": "",
        "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2025-09-18T13:00:04Z",
        "displayTime": "2025-09-18T13:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177",
          "originalWidth": 900,
          "originalHeight": 598,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2yFNHFE.NEelN3EcxccP6Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177.cf.webp",
              "width": 900,
              "height": 598,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tL0vRMsfrFLR6L27GP3atA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-gilead-sciences-130004097.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-gilead-sciences-130004097.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-18T11:00:00+00:00",
    "headline": "Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer",
    "summary": "Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the completion of the safety run-in and the determination of recommended Phase 2 dose (RP2D) for its ongoing Phase 1b/2 STARt-002 trial. The study, evaluating Marengo's dual T-cell agonist invikafusp alfa in combination with TRODELVY® (sacituzumab govitecan-hziy), Gilead's approved TROP2-directed antibody-drug c",
    "url": "https://finance.yahoo.com/news/marengo-therapeutics-advances-start-002-110000593.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "48e16f72-c57c-3952-9f8b-d9a008d71c05",
      "content": {
        "id": "48e16f72-c57c-3952-9f8b-d9a008d71c05",
        "contentType": "STORY",
        "title": "Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer",
        "description": "",
        "summary": "Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the completion of the safety run-in and the determination of recommended Phase 2 dose (RP2D) for its ongoing Phase 1b/2 STARt-002 trial. The study, evaluating Marengo's dual T-cell agonist invikafusp alfa in combination with TRODELVY® (sacituzumab govitecan-hziy), Gilead's approved TROP2-directed antibody-drug c",
        "pubDate": "2025-09-18T11:00:00Z",
        "displayTime": "2025-09-18T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f205ea4aa8c624f81f257f797362e47c",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "(PRNewsfoto/Marengo Therapeutics)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XuiBDrvPVC5wraLb7_5cQQ--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f205ea4aa8c624f81f257f797362e47c.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TtnkmqZkYLPAI61TIqi4Ww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f205ea4aa8c624f81f257f797362e47c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/marengo-therapeutics-advances-start-002-110000593.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/marengo-therapeutics-advances-start-002-110000593.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-18T01:16:00+00:00",
    "headline": "Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management",
    "summary": "SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (\"Fangzhou\" or the \"Company\") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“Gilead”) 2025 Multi-Channel Conference in Shanghai. Founder, Chairman and CEO Dr. Xie Fangmin was invited as a keynote guest at the event. The award recognizes Fangzhou’s achievements in advancing innovation and digitalization in healthcare, underscoring its shared commitment with Gil",
    "url": "https://finance.yahoo.com/news/fangzhou-wins-gilead-award-excellence-011600118.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "aebce1ba-48ab-3e01-972f-12017f085d30",
      "content": {
        "id": "aebce1ba-48ab-3e01-972f-12017f085d30",
        "contentType": "STORY",
        "title": "Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management",
        "description": "",
        "summary": "SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (\"Fangzhou\" or the \"Company\") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“Gilead”) 2025 Multi-Channel Conference in Shanghai. Founder, Chairman and CEO Dr. Xie Fangmin was invited as a keynote guest at the event. The award recognizes Fangzhou’s achievements in advancing innovation and digitalization in healthcare, underscoring its shared commitment with Gil",
        "pubDate": "2025-09-18T01:16:00Z",
        "displayTime": "2025-09-18T01:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/a5365b0ad26025875f3f6368ba1fd3a1",
          "originalWidth": 1280,
          "originalHeight": 1920,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uddG3Vc3ls4hz5MhqSDbew--~B/aD0xOTIwO3c9MTI4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/a5365b0ad26025875f3f6368ba1fd3a1.cf.webp",
              "width": 1280,
              "height": 1920,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7zuZY_6BQpawCEmBzR0imQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a5365b0ad26025875f3f6368ba1fd3a1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fangzhou-wins-gilead-award-excellence-011600118.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fangzhou-wins-gilead-award-excellence-011600118.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "6086.HK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]